Nicoletta Colombo, MD, PhD, discusses why metronomic chemotherapy dosing and careful regimen design may have driven the success of the KEYNOTE-B96 trial.

Andrea Necchi, MD, shared SunRISe-4 primary results demonstrating higher pathologic response and relapse-free survival rates with TAR-200 plus sacituzumab compared with checkpoint inhibitor monotherapy, with no new safety signals observed.

Felix Guerrero-Ramos, MD, outlines molecular and pharmacologic findings from SunRISe-1, including the high prevalence of TP53 alterations and the extended drug exposure achieved with the TAR-200 intravesical delivery system.

Pranav Garimella, MBBS, MPH, emphasizes that pharmacists are essential partners in managing chronic kidney disease, ensuring safe medication use, adherence, and coordinated care alongside physicians.

Whether they are collaborating with other health care professionals, helping with medication adherence, or educating patients, the pharmacist has a crucial role in every setting.

Ron Lanton outlines enforcement uncertainty and downstream effects on biosimilars, specialty drugs, and pharmacy supply chains under most favored nation pricing proposals.

Steven Pipe, MD, highlights the growing importance of pharmacists in hemophilia care as new therapies expand treatment complexity and require specialized expertise.

Canomiks enhances consumer trust in the supplement industry through WhatToTrust, a platform evaluating product safety, efficacy, and scientific validation.

Pharmacists emphasize the importance of RSV awareness, testing, and vaccination for older adults and high-risk infants to enhance community health.